Eloxx Doses First Patients in Phase 2b EXACT Study
Eloxx Pharmaceuticals dosed the first two patients in its global Phase 2b EXACT study for nonsense mutation Alport syndrome and received FDA clearance for a Phase 2 EXPRESS study in ADPKD, signaling continued clinical development despite limited current market visibility.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed